Aeon Global Health competitors

Michael Morrissey is a President/CEO at EXELIXIS, INC.; Board Member at EXELIXIS, INC.; and Board Member at XW LABORATORIES INC and is based in Danville, California. He has experience at Schering AG and has worked as VP:Discovery Research at Berlex Biosciences; Senior Scientist at Novartis; and Senior VP:Discovery at EXELIXIS, INC.. Michael studied at Harvard University and University of Wisconsin Oshkosh.

Tom Schoenherr comes to Ambry with more than 20 years of experience in the molecular diagnostics space, most recently as the CCO of Omada Health where he was responsible for driving business growth and increasing market share. He also served in similar roles at Counsyl, Quest Diagnostics, Siemens Healthcare and Abbott Diagnostics. As Ambry’s Chief Commercial Officer, Tom will be responsible for the execution of Ambry’s goto market strategy and will oversee all commercial functions including service, support, sales, marketing, business development, managed care and genetic specialists. Tom earned his BS from Michigan State University and completed his Executive Business Development Program from the University of Notre Dame.

Andrew Walton is a Chief Executive Officer at Miraca Life Sciences and Board Member at OXFORD IMMUNOTEC GLOBAL PLC. He has worked as Senior VP/CIO at LABORATORY CORP OF AMERICA HOLDINGS, Executive In Charge at LABORATORY CORP OF AMERICA HOLDINGS, and Exec VP:Strategic Planning at LABORATORY CORP OF AMERICA HOLDINGS. Andrew attended Yale University and Harvard Business School.

Michelle Finnerty is an Executive Assistqnt / Office Services Administrator at Amentum; Notary Public at State of Maryland; and Ancelmo Lopes, President/CEO; Todd Gardner, CFO; Jay Zimmerman, COO at Ameritox and is based in Baltimore, Maryland. She has worked as excellent customer service at Financial Reconciler, Corporate Payroll; Executive Assistant to Archbishop Wm E. Lori at Archdiocese of Baltimore; and Executive Assistant to CNO, VP of Nursing at GBMC Healthcare Inc. Michelle attended Walden University between 2017 and 2017, University of Baltimore between 2011 and 2014, and Community College of Baltimore County between 2010 and 2010.

Jake Orville has 20+ years of diagnostic, life science and medical device management experience within both established and emerging markets. As the General Manager of Pipeline at Exact Sciences, Jake leads the company's efforts to develop and advance solutions for earlier detection and life changing answers across the cancer continuum. Prior to Exact Sciences, Jake co-founded Cleveland HeartLab, Inc. (CHL) and served as the CEO from inception to exit. CHL was spun-out of the Cleveland Clinic to develop and rapidly commercialize unique diagnostic technologies, with applications in cardiovascular and inflammatory indications. CHL was acquired by Quest Diagnostics in December 2017. Jake Served as the General Manager of the Cardiometabolic & Endocrinology Franchise at Quest. Under Jake’s leadership, CHL was recognized as Ohio’s Venture of the Year (2012); received an Economic Impact Award by the city of Cleveland for job creation (2013) and was recognized as an Inc. 500 fastest growing private company in the US (2014). Jake has been recognized as a Top 50 Smart Leader by Smart Magazine and received the Annual Innovation Award in 2018 Prior to co-founding Cleveland HeartLab, Jake was CEO of Prognostix and held Senior Management positions with two publically traded companies (NextGen Sciences - AIM NGG.L; Third Wave Technologies - Nasdaq TWTI). He is a co-founder of Viridian Medical and Tolera Therapeutics and currently sits on the Board of Directors for The Wisconsin Women’s Health Foundation. Jake has raised capital from multiple sources, including top tier venture funds, strategic and international investors as well as angels, family offices and state funding sources. A well recognized entrepreneur, he has given many lectures on innovation, commercialization, early stage ventures, technology transfer and intellectual property. Jake received his Bachelor of Arts from the University of Massachusetts, Amherst and his MBA from the University of Wisconsin, Madison.